Novo analysis puts CagriSema weight loss at 25% in women
The post-hoc look at late-stage data separates out female participants from the broader REDEFINE program readout.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 20 12:30 ETSource: Reuters
The wire
- 01Novo Nordisk reported an analysis showing women treated with CagriSema lost an average of 25% of body weight.
- 02CagriSema pairs semaglutide with the amylin analog cagrilintide, and sex-specific response data informs how clinicians counsel patients on expected results.
- 03This is a post-hoc subgroup analysis rather than a prespecified endpoint, so the figure should be read alongside the full trial result.
From the source
Read at reuters.comNovo's CagriSema helped women lose 25% of weight on average, analysis shows
